MARK EICHENBAUM: Open Payments
NPI 1871764977 · SAINT PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$343 in 16 payments from 10 companies in 2025. Trend: 2023 $535 · 2024 $419 · 2025 $343
Food & beverage: $343
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $70 |
| GlaxoSmithKline, LLC. | 2 | $56 |
| Novartis Pharmaceuticals Corporation | 2 | $54 |
| Novo Nordisk Inc | 2 | $44 |
| Insmed, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $22 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $21 |
| Lilly USA, LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| PFIZER INC. | 1 | $15 |
Products named: AIRSUPRA, TRELEGY ELLIPTA, LEQVIO, Ozempic, Arikayce, VYALEV, Quviviq, MOUNJARO.
Industry payments across FL — which companies pay providers there.
